HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and increased the price target from $12 to $15.

March 13, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Ocular Therapeutix and raises the price target from $12 to $15.
The upgrade in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100